1. Lipid levels and major adverse cardiovascular events in patients initiated on statins for primary prevention: an international population-based cohort study protocol
- Author
-
Joseph E Blais, Ralph Kwame Akyea, Annelize Coetzee, Amy HY Chan, Wallis CY Lau, Kenneth KC Man, Jeff Harrison, Esther W Chan, Kebede A Beyene, Ian CK Wong, and Stephen Weng
- Subjects
hydroxymethylglutaryl-coa reductase inhibitors ,cholesterol ,major adverse cardiovascular events ,primary prevention ,cohort studies ,Medicine (General) ,R5-920 - Abstract
Background: Clinical guidelines recommend specific targets for low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) for primary prevention of cardiovascular disease (CVD). Furthermore, individual variability in lipid response to statin therapy requires assessment of the association in diverse populations. Aim: To assess whether lower concentrations of LDL-C and non-HDL-C are associated with a reduced risk of major adverse cardiovascular events (MACE) in primary prevention of CVD. Design & setting: An international, new-user, cohort study will be undertaken. It will use data from three electronic health record databases from three global regions: Clinical Practice Research Datalink, UK; PREDICT-CVD, New Zealand (NZ); and the Clinical Data and Analysis Reporting System, Hong Kong (HK). Method: New statin users without a history of atherosclerotic CVD, heart failure, or chronic kidney disease, with baseline and follow-up lipid levels will be eligible for inclusion. Patients will be classified according to LDL-C (
- Published
- 2020
- Full Text
- View/download PDF